当前位置: > 信息科学 > 诺禾致源和Pacbio决定合作开发基于三代Sequel测序的精准医疗应用

诺禾致源和Pacbio决定合作开发基于三代Sequel测序的精准医疗应用

据来自GenomeWeb的消息,诺禾致源(Novogene)和Pacbio决定合作开发基于三代Sequel测序的精准医疗应用。另外,双方将在样品处理、数据分析、算法研发和数据库建设等相关领域展开合作。此合作的相关财务信息并未公布。

NEW YORK (GenomeWeb) – Novogene and Pacific Biosciences said today that they plan to co-develop and co-market applications based on PacBio's Sequel system that focus on basic and translational research in precision medicine.

In particular, the firms will focus on methods for sample processing, workflow automation, algorithm development, and database construction.

Financial and other details of the agreement were not disclosed.

Novogene is a sequencing service provider based in Beijing, but also has branches in Hong Kong, the US, and the UK. It operates 10 Sequel systems and has expertise in developing sample preparation, data analysis, and interpretation tools.

支付宝赞助
微信赞助

诺禾致源和Pacbio决定合作开发基于三代Sequel测序的精准医疗应用:等您坐沙发呢!

发表评论

表情
还能输入210个字